Back to overview

Transmembrane interactions in lymphocytes: Sphingolipid micro- domains in lymphocyte signaling

English title Transmembrane interactions in lymphocytes: Sphingolipid micro- domains in lymphocyte signaling
Applicant Hoessli Daniel
Number 102158
Funding scheme Project funding
Research institution Département de Pathologie et Immunologie Faculté de Médecine / CMU Université de Genève
Institution of higher education University of Geneva - GE
Main discipline Cellular Biology, Cytology
Start/End 01.10.2003 - 30.09.2006
Approved amount 202'938.00
Show all

Keywords (3)

membranes; lymphocytes; transmembrane signaling

Lay Summary (English)

Lay summary
In all B lymphoma cell lines tested, Lyn and Cbp/PAG appear to be associated and selectively concentrated in sphingolipid-rich, raft microdomains, wherein the Lyn activity is optimal. The Lyn-Cbp/PAG interaction thus relies on protein-protein contacts and its catalytic function is dependent on the sphingolipid environment of the raft microdomains. This activity does not require cross-linking of surface components, unlike what is needed to signal through rafts (crosslinking of GPI-linked surface proteins, for instance). The lymphoma signalling machinery is therefore constitutively activated (constitutively activated signalosome). With the exception of Burkitt-derived Raji cells that are resistant to cell death, despite inhibition of Lyn in rafts, all other B-lymphoma cell lines undergo cell death following Lyn inhibition.Moreover, in selected cell lines, we have shown that Lyn inhibition can also result from altering the raft membrane.
Several B-lymphoma cell lines are therefore vulnerable at the Lyn kinase, as well as in their raft microdomain organization. We think that our results open up new and realistic therapeutic possibilities.
Direct link to Lay Summary Last update: 21.02.2013

Responsible applicant and co-applicants


Associated projects

Number Title Start Funding scheme
120368 Transmembrane interactions in lymphocytes: signaling alterations in lymphomas and myelomas tumor cells 01.04.2008 Project funding